title: [Is it cost-benefit acceptable the change of EPO subcutaneous to intravenous administration in patients in hemodialysis?].
authors.forename: R
authors.initials: R
authors.lastname: Peces
mesh_terms: D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D007275:Injections, Intravenous / Q000191:economics; D007279:Injections, Subcutaneous / Q000191:economics
chemical_list: D004921:Erythropoietin